4.3 Article

Rapamycin in aging and disease: maximizing efficacy while minimizing side effects

期刊

ONCOTARGET
卷 7, 期 29, 页码 44876-44878

出版社

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.10381

关键词

mTOR; target of rapamycin; healthspan; mitochondria; mitochondria disease

资金

  1. NIH [F32AG050444]
  2. Glenn Foundation
  3. University of Washington Nathan Shock Center of Excellence in the Basic Biology of Aging [P30AG013280]
  4. Alzheimer's Disease Research Center [P50AG005136]

向作者/读者索取更多资源

Experimental geroscience has identified rapamycin as a top candidate for promoting healthy aging and longevity in mammals. As multiple independent studies have successfully reproduced the lifespan and healthspan promoting effects of rapamycin, the focus has shifted to possible translational use. While a promising compound, clinical use of rapamycin is limited by concerns of side effects associated with the drug. Studies aimed at defining optimal dosage regimen, delivery route, and formulation will allow for benefits to be maximized while reducing side effects.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据